DK1416965T3 - Assayfremgangsmåde til Alzheimers sygdom - Google Patents
Assayfremgangsmåde til Alzheimers sygdomInfo
- Publication number
- DK1416965T3 DK1416965T3 DK02766022T DK02766022T DK1416965T3 DK 1416965 T3 DK1416965 T3 DK 1416965T3 DK 02766022 T DK02766022 T DK 02766022T DK 02766022 T DK02766022 T DK 02766022T DK 1416965 T3 DK1416965 T3 DK 1416965T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- alzheimer
- beta
- assay procedure
- preclinical
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US31322401P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| PCT/US2002/026321 WO2003015617A2 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1416965T3 true DK1416965T3 (da) | 2008-05-05 |
Family
ID=27405654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02766022T DK1416965T3 (da) | 2001-08-17 | 2002-08-16 | Assayfremgangsmåde til Alzheimers sygdom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1416965B8 (https=) |
| JP (2) | JP4511830B2 (https=) |
| AT (1) | ATE381346T1 (https=) |
| CA (1) | CA2457145C (https=) |
| CY (1) | CY1107901T1 (https=) |
| DE (1) | DE60224200T2 (https=) |
| DK (1) | DK1416965T3 (https=) |
| ES (1) | ES2295401T3 (https=) |
| PT (1) | PT1416965E (https=) |
| WO (1) | WO2003015617A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0108676B8 (pt) | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
| PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE602004027348D1 (de) | 2003-02-10 | 2010-07-08 | Applied Molecular Evolution | Abeta-bindende moleküle |
| EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| PT2121754E (pt) | 2007-01-18 | 2015-05-11 | Lilly Co Eli | Fab de beta-amilóide peguilado |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
| WO2011070174A1 (en) | 2009-12-11 | 2011-06-16 | Araclon Biotech, S.L. | Methods and reagents for improved detection of amyloid beta peptides |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| MX2016006584A (es) * | 2013-11-20 | 2016-09-06 | Univ Iowa Res Found | Métodos y composiciones para tratar los depósitos de amiloide. |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR102496845B1 (ko) * | 2018-08-08 | 2023-02-08 | 서울대학교산학협력단 | 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE667959T1 (de) * | 1992-10-26 | 2000-04-20 | Dale B Schenk | VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID. |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
| BRPI0108676B8 (pt) * | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
-
2002
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en not_active Ceased
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010044078A (ja) | 2010-02-25 |
| CA2457145C (en) | 2010-12-21 |
| JP4511830B2 (ja) | 2010-07-28 |
| ATE381346T1 (de) | 2008-01-15 |
| WO2003015617A3 (en) | 2004-01-29 |
| JP5162553B2 (ja) | 2013-03-13 |
| EP1416965B1 (en) | 2007-12-19 |
| PT1416965E (pt) | 2008-04-01 |
| EP1416965A4 (en) | 2005-11-02 |
| CY1107901T1 (el) | 2013-09-04 |
| DE60224200D1 (de) | 2008-01-31 |
| HK1061960A1 (en) | 2004-10-15 |
| WO2003015617A2 (en) | 2003-02-27 |
| DE60224200T2 (de) | 2008-07-10 |
| JP2004538477A (ja) | 2004-12-24 |
| ES2295401T3 (es) | 2008-04-16 |
| EP1416965A2 (en) | 2004-05-12 |
| CA2457145A1 (en) | 2003-02-27 |
| EP1416965B8 (en) | 2008-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107901T1 (el) | Μεθοδος προσδιορισμου για ασθενεια alzheimer | |
| EP1944040A3 (en) | Assay method for Alzheimer's disease | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| DE60235746D1 (de) | Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation | |
| DK1351707T3 (da) | Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser | |
| PT2298347E (pt) | Proteínas quiméricas de fator de coagulação para o tratamento de um disturbio hemostático | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| WO2000018954A3 (en) | Use of pex in the treatment of metabolic bone diseases | |
| DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
| EP1421104A4 (en) | HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE | |
| DK1353948T3 (da) | Oplöselige biologiske analoge til bata-amyloidpeptid | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
| DK1406927T3 (da) | Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose | |
| WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| AU2002366555A1 (en) | Diagnostic for early stage alzheimer's disease | |
| ATE473295T1 (de) | Nukleotidträger zur diagnose und therapie oraler erkrankungen | |
| DE60303360D1 (de) | Diagnostische und therapeutische verwendung des caps | |
| AU2003215667A1 (en) | Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases | |
| FR2837284B1 (fr) | Methode de diagnostic serologique in vitro des endocardites infectieuses | |
| ATE261584T1 (de) | Plasmasammlungen von mehr als 200 gesunden patienten und davon abgeleiteter kalibrierstandard | |
| DE60111519D1 (de) | Chemische modifizierung von harn von säugern |